Travere Therapeutics, Inc. (TVTX) Earnings
Travere Therapeutics, Inc. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.05. TVTX has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise +43.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-0.30 | $-0.39 | -30.0% | $127M | -6.6% |
| Feb 19, 2026 | $0.03 | $0.03 | +0.0% | $130M | -2.3% |
| Oct 30, 2025 | $-0.31 | $0.28 | +190.3% | $165M | +12.2% |
| May 1, 2025 | $-0.55 | $-0.47 | +14.5% | $82M | -8.0% |
| Feb 20, 2025 | $-0.58 | $-0.73 | -25.9% | $75M | +3.3% |
| Oct 31, 2024 | $-0.70 | $-0.70 | +0.0% | $63M | -12.0% |
| Aug 1, 2024 | $-0.87 | $-0.90 | -3.4% | $54M | -6.3% |
| Feb 15, 2024 | $-1.27 | $-1.16 | +8.7% | $45M | +8.5% |
| Aug 3, 2023 | $-1.16 | $-1.13 | +2.6% | $60M | +11.1% |
| May 4, 2023 | $-1.18 | $-1.27 | -7.6% | $57M | +12.6% |
| Feb 23, 2023 | $-1.04 | $-1.03 | +1.0% | $56M | +5.4% |
| Oct 27, 2022 | $-0.97 | $-1.09 | -12.4% | $53M | -1.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Achieved first FDA approval in FSGS, established Filspari as first and only approved medicine for FSGS. - Exceptional commercial performance in IgA nephropathy with record new patient start forms. - Dosed first new patient in phase three Harmony study of PEG-2-batinase following restart of enrollment. - Dr. Jula Enrich discussed Filspari's approval in FSGS, including patient eligibility and data from studies. - Peter Hirma shared commercial performance, Filspari's revenue growth, and strong launch in FSGS with early positive feedback. - Chris Klein provided financial update, including total revenue, operating expenses, net loss/gain, and cash position.
Guidance
- FSGS is expected to further contribute to top-line trajectory. - Continued strong demand and the product are expected to drive sustained revenue growth.
Segment performance
In the first quarter, Filspari's U.S. net product sales grew approximately 88% year-over-year to $105.2 million. Viola and Fiola EC contributed $19.3 million in U.S. product sales during the first quarter, and license and collaboration revenue was $2.7 million. Total revenue for the first quarter was $127.2 million. Filspari's revenue contribution in IgA nephropathy and FSGS is significant, with an estimated potential peak sales opportunity of $3 billion for Filspari.
Analyst Q&A
Q: Will speaking on for Joe asked about FSGS launch progress vs IGAN launch and if early seen is supportive of faster FSGS launch.
A: Peter said they are confident in faster uptake in FSGS due to high unmet need, strong brand awareness, and payer access foundation.
Q: Greg on for Tyler asked about FSGS PSFs recorded, proportion of early starts via payer auth vs exceptions/appeals.
A: Peter said too early to quantify but everything seen confirms faster uptake than initial IGAN launch in terms of demand and payer approval rate.
Q: Anupam asked about FSGS launch physician education on product label.
A: Peter said need to build awareness, educate on label like not being in nephrotic syndrome, Jule added positive feedback from physicians and alignment with KDGO.
Q: Prakhar asked about FSGS uptake comparison to IGAN launch and access for secondary FSGS.
A: Eric said not providing guidance on PSF by indication, Peter said seen higher first pass approval at payer level than initial IGAN.
Q: Vamil asked about confusion on nephrotic syndrome history and prescribing Filspari.
A: Jule said history of nephrotic syndrome should not reserve physician, aligned with KDGO, Peter said payers understand nephrotic syndrome is dynamic.
Q: Gavin asked about discontinuation rates in IgA nephropathy and comparison to phase three.
A: Peter said compliance and persistence rates high, Jule said consistent with PROTECT trial.
Q: Sadia asked about conversion rate of patient start forms to treatment.
A: Peter said continue to convert rapidly, no drop-offs seen.
Q: Laura asked about competitive landscape for IgA nephropathy and PSF increase with FSGS approval.
A: Peter said market growth not from competitive share but growing market, Philspari well positioned, Laura's PSF increase in Q1 from IG nephropathy.
Q: Maury asked about estimating IGAN PSFs going forward and competitive launch of Atuka.
A: Peter said no reason to believe can't continue performance, peak sales based on growth in both indications.
Q: Jason asked about Filspari's use sequence in FSGS.
A: Jula said vast majority of patients on RAS inhibitor, SGLT2 inhibitor used but not as prevalent, Joel added on immunosuppressant use in active nephrotic syndrome.
Q: Alex asked about shipping week impact and PEG-2-batinase phase three.
A: Chris said don't typically break down individual weeks, Bill said had breakthrough therapy designation, reached alignment on endpoint with FDA for Harmony study